# A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

> **NCT00818038** · — · COMPLETED · sponsor: **Biogen** · enrollment: 30 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** BG0002 (natalizumab)

## Key facts

- **NCT ID:** NCT00818038
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818038, "A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00818038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*